Evidence map›Paper›PMID 40616090›Full record

ArticleRespiratory research2025

Proteomic discovery analysis of quantitatively assessed emphysema in the general population. The MESA Lung Study.

Daniel E Guzman, Lisa Ruvuna, Claire J Guo, Yifei Sun, Katherine A Pratte, Ani W Manichaikul, John S Kim, Wendy S Post, Alain G Bertoni, Norrina B Allen and 20 more

Abstract read
In one paragraph

Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Circulating proteomic landscape of lung function.The European respiratory journal · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Daniel E GuzmanDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA. deg2175@cumc.columbia.edu.
Lisa RuvunaGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Claire J GuoDepartment of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Yifei SunDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Katherine A PratteNational Jewish Health, Denver, CO, USA.
Ani W ManichaikulCenter for Public Health, University of Virginia School of Medicine, Charlottesville, VA, USA.
John S KimDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Wendy S PostDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alain G BertoniDivision of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Norrina B AllenCenter for Epidemiology and Population Health, Northwestern University, Chicago, IL, USA.
Karol E WatsonDepartment of Medicine, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA.
James S PankowDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Eric A HoffmanDepartment of Radiology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Ruth F DubinDepartment of Medicine, University of Texas Southwestern, Dallas, TX, USA.
Rajat DeoDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Igor Z BarjaktarevicDepartment of Medicine, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA.
Eugene R BleeckerDepartment of Medicine, The University of Arizona Health Sciences, Tucson, AZ, USA.
Christopher B CooperDepartment of Medicine, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA.
Victor E OrtegaDepartment of Medicine, Division of Pulmonary Medicine, Mayo Clinic, Scottsdale, AZ, USA.
Annette T HastieDepartment of Medicine, Wake Forest School of Medicine, Winston-Salem, MD, USA.
Robert PaineDivision of Respiratory, Critical Care and Occupational Pulmonary Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
James Michael WellsDepartment of Medicine, University of Michigan, and VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Jeffrey L CurtisDepartment of Medicine, University of Michigan, and VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Edwin K SilvermanChanning Division of Network Medicine and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Prescott G WoodruffDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Christine Kim GarciaDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Jerome I RotterThe Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA USA, USA.
Russell P BowlerGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Peter GanzDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
R Graham BarrDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
GENETIC EPIDEMIOLOGY OF COPD (COPD GENE) TASK A: STUDY VISIT 4, COLLECTION OF COPDGENE STUDY DATA ANDBIOSPECIMENS AND OVERSIGHT OF THE COPDGENE STUDY75N92023D00011 · NHLBI · NATIONAL JEWISH HEALTH · PI NEWMAN, LEE S · 2023 to 2025
$29.6M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Pulmonary microvascular perfusion in the Multi-Ethnic Study of AtherosclerosisR01HL077612 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI R Graham BARR · 2004 to 2026
$18.8M
Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary Disease (COPD)R01HL093081 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI R Graham BARR · 2008 to 2026
$17.2M
Chronic obstructive pulmonary disease in non-smokersR01HL130506 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HERBSTMAN, JULIE BETH, SMITH, BENJAMIN M. · 2016 to 2025
$6.3M
Biomarker of Lung Disease in African AmericansR01HL137995 · NHLBI · NATIONAL JEWISH HEALTH · PI BOWLER, RUSSELL PAUL, KECHRIS-MAYS, KATHERINA · 2018 to 2021
$3.4M
Proteomics of Cardiovascular Risk: The Multiethnic Study of AtherosclerosisR01HL159081 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEO, RAJAT, DUBIN, RUTH · 2021 to 2024
$2.4M
Training Program in Population Science of Respiratory DiseasesT32HL144442 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BARR, R GRAHAM · 2019 to 2023
$730k
National Heart, Lung, and Blood Institute,United States HHSN268200900013C-HHSN268200900020CNCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1-TR-000040NHLBI NIH HHS 1R01HL137995NHLBI NIH HHS 75N92023D00011NHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS R01 HL077612NHLBI NIH HHS R01-HL077612NHLBI NIH HHS R01 HL093081NHLBI NIH HHS R01 HL130506NHLBI NIH HHS R01-HL130506NHLBI NIH HHS R01 HL137995NHLBI NIH HHS R01 HL159081NHLBI NIH HHS R01HL159081NHLBI NIH HHS T32 HL144442NHLBI NIH HHS T32-HL144442NHLBI NIH HHS U01 HL089897NHLBI NIH HHS U01 HL137880NIDDK NIH HHS DK063491NIDDK NIH HHS P30 DK063491NIEHS NIH HHS P30 ES005605NIH HHS 75N92023D00011
6 · The paper itself

Abstract

backgroundPulmonary emphysema occurs frequently in older adults, often without airflow limitation. Its presence predicts symptoms, respiratory hospitalizations and deaths, and all-cause mortality. Proteomics may provide further insights into emphysema pathogenesis and inform therapeutic targets.

objectiveWe performed a proteomic discovery analysis of percent emphysema on computed tomography (CT) in a population-based, multiethnic sample from the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Replication was performed in two chronic obstructive pulmonary disease (COPD)-based studies, the SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS) and the Genetic Epidemiology of COPD (COPDGene) Study.

methodsMESA recruited participants from the general population in 2000-02. The MESA Lung Study performed full-lung CT scans in 2010-12. Percent emphysema was defined as the percentage of lung voxels < -950 Hounsfield units. Over 7,200 plasma aptamers were measured via SomaScan. Cross-sectional linear and least absolute shrinkage and selection operator (LASSO) regression models were adjusted for demographics, anthropometrics, smoking, renal function, and scanner parameters. Statistical significance was defined as a false discovery rate p-value < 0.05. Gene Ontology (GO)/Reactome enrichment analyses were performed. LASSO-selected proteins' predictive performance was evaluated.

resultsAmong 2,504 participants in the MESA Lung Study, mean age was 69.4 years, 1,291 had ever smoked, and median percent emphysema-like lung was 1.4%. In total, 1,234 aptamers were significantly associated with percent emphysema in the MESA Lung Study, and 35 replicated in the SPIROMICS and COPDGene Studies. Novel associations included protein family with sequence similarity (FAM) 177A1, syntenin-2, ubiquitin carboxyl-terminal hydrolase 25, and uncharacterized protein C20orf173. Previously identified emphysema-associated proteins included soluble advanced glycosylation end product-specific receptor (sRAGE), protein S100-A12, high mobility group protein B1, and roundabout homolog 2. Enrichment analyses identified 40 GO biological processes, including chemokine production and regulation and cell-cell adhesion and regulation, and two Reactome pathways, including RAGE signaling. In tenfold cross-validation, novel proteins were largely retained by LASSO (R

conclusionsThis analysis in a general population sample identified novel and previously characterized proteins whose functional roles were validated by GO/Reactome enriched pathways, offering new insights into emphysema pathophysiology and therapeutics.

Indexed as

LungPopulation SurveillanceProteomicsPulmonary EmphysemaAgedAged, 80 and overCross-Sectional StudiesFemaleHumansMaleMiddle AgedTomography, X-Ray ComputedBiomarkersEmphysemaProteomics

Identifiers

PMID40616090
PMCPMC12228189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.